logo
Drugs like Ozempic aren't changing negative narratives around diet and weight

Drugs like Ozempic aren't changing negative narratives around diet and weight

Irish Times5 days ago
Friends keep asking me what I think about
Ozempic
. I know they're asking because I've written about food history, gender and eating disorders, but until recently I wasn't sure what I thought, wasn't sure that someone who has never had metabolic disease or lived in a body that attracted comment had any business having opinions about the drugs called GLP1 agonists.
I support any development that undermines the idea that bodyweight has a moral aspect, or that individuals control the size of their bodies. We are shaped in every way by environment, society and genetics far more than by the small scope of personal choice within those determinants. Health is mostly determined by heredity and wealth. So if the new drugs stop people insisting that self-discipline and self-starvation are the answer to fatness, all to the good.
[
Sarah Moss: 'I'm a classic first child. A driven overachiever. Slightly neurotic'
Opens in new window
]
But I'm not sure they're generally helping us live better lives. I gather GLP1 agonists are good as diabetes medication – not an area in which I am qualified to opine. Their rising use for other purposes seems to be correlated to increasing media excitement about extreme thinness, particularly in women, which is demoralising to those of us who grew up with heroin chic and the worship of emaciation and have lived in the shadow of those ideals ever since.
If the drugs are changing narratives about diet and weight, I'm not seeing it. There's no decline in mindless writing about and advertising of 'guilt-free' foods and 'guilty pleasures'. (What you put in your mouth has no bearing on your moral worth. The only sinful foods are those harmfully produced.)
READ MORE
I understand that these medications work by depriving people of pleasure in eating. I'd argue that pleasure is politically and ideologically important as well as nice, that without pleasure we fall prey to the idea that life is nothing but scarcity and survival, which leads quickly to the idea that life is a competition and weakness is failure, at which point you're well down the road to dark places we don't need to go.
Taking expensive drugs to make daily life less fun so you take up less space doesn't sound to me like the kind of choice made by happy people in a functional society, though you could argue that unhappy people in a dysfunctional society – for example, fat people hoping to be paid, promoted and desired as much as their thinner colleagues in Europe today – might perfectly sensibly make such decisions. Getting thin to succeed in a fat-phobic society is still an understandable individual solution to a structural problem.
And it seems to me that the big structural problem here is not that people are fat but that we have created and continue to promote a food system that makes most consumers unwell, and are now creating and promoting a regime of medication that, at great financial and personal cost, claims to counteract the effects of that food system. We're all being sold ultra-processed, intensively farmed food that makes us and our planet sick, and then being sold drugs that moderate the effect of that food on individual bodies but compound the harm to the environment. I am certain that the same shareholders profit from the manufacture and sale of the food that causes the problem and the drugs that treat it.
Ozempic's popularity is a symptom and driver of social and economic injustice, and I wish we could spend some of its cost on systemic change instead
None of which means that I blame any individual for making whatever decisions seem necessary to cope. I only note that the troubles that show up in our bodies rarely began there, and therefore the sustainable solutions won't begin with injections.
There are countries that have been able to reduce the proportions of intensively produced and processed foods consumed by their populations, especially by children. There are examples of local, regional and national governments creating and sometimes imposing healthier and more sustainable environments, but it can't happen without at least some popular demand, and the established interests and beneficiaries of harmful systems will never want such change.
So what I think about Ozempic is that its popularity is a symptom and driver of social and economic injustice, and I wish we could spend some of its cost on systemic change instead. We could subsidise the production and transport of a lot of fresh local produce and build a lot of playgrounds, sports facilities and bike lanes for what we lose paying pharmaceutical companies to heal us from their absence. And it would be much more fun.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Toolkit addresses ‘paralysis' in sharing information on vulnerable adults between healthcare organisations
Toolkit addresses ‘paralysis' in sharing information on vulnerable adults between healthcare organisations

Irish Times

time10 hours ago

  • Irish Times

Toolkit addresses ‘paralysis' in sharing information on vulnerable adults between healthcare organisations

The Data Protection Commission (DPC) has launched an adult safeguarding 'toolkit' to address misunderstandings about how to protect the data of at-risk adults in health and social care settings. The introduction of the General Data Protection Regulation ( GDPR ) has caused 'paralysis' where people are concerned that they shouldn't share data even if they can, DPC chairman and commissioner for data protection Des Hogan said. For example, residential care centres may not receive relevant health information about prospective residents, leading to 'a whole suite of issues that would unfold once the resident is already settled in there', said Bibiana Savin, chief executive of Sage Advocacy . Ms Savin further outlined misunderstandings relating to the gathering of a vulnerable adult's data from cameras and recording devices, and family members' rights to request data on behalf of their loved one. READ MORE Under GDPR, sensitive data can be shared where there is consent, in performance of a contract, to comply with a legal obligation and for vital, public or legitimate interests. In April 2024, the Law Reform Commission proposed a new law on adult safeguarding to address a gap in the regulatory framework. 'There's a lack of positive obligations and clear legal basis for data sharing,' said David Murphy, deputy commissioner of the DPC. Positive obligations are typically duties imposed on official bodies to take specific actions to protect individuals' fundamental rights. While clear positive obligations to share data in this context are being developed, the DPC's new toolkit aims to avoid blockages in how information flows between systems where there is a legal basis for sharing personal data. 'We would like to change the mindset, to factoring in 'What harms could arise to the individual if I don't share their data',' Mr Murphy said. The DPC defines vulnerable adults broadly, including individuals suffering from physical or mental conditions, children with additional needs reaching the age of majority, people subject to domestic violence or coercive control, experiencing homelessness, financial abuse or trafficking. [ Abusers using data protection law to get details on victims Opens in new window ] The toolkit follows the DPC's work on safeguarding children's data and expands the focus to a wide range of vulnerable groups in society. The commission has been engaging with various stakeholders in the social care and health systems for the past two years to develop the toolkit. Mr Hogan said at the launch on Thursday, 'we need to get away from this paternalism which has permeated our society for an awful long period of time ... into the position where we are defending and protecting rights'. 'As we move our way into a new digital world, it is just so important that we get this right,' he said.

Teen who left care and lost follow-on housing tried to take their own life, court hears
Teen who left care and lost follow-on housing tried to take their own life, court hears

Irish Times

time19 hours ago

  • Irish Times

Teen who left care and lost follow-on housing tried to take their own life, court hears

A teenager with a personality disorder who left special care recently has lost their follow-on accommodation is using drugs, facing criminal charges, has been stabbed and has attempted to take their own life, the High Court heard. The case, one of 15 involving the most at-risk children and young people in or just out of special care, illustrated why mental health legislation 'should be looked at again', said Mr Justice John Jordan on Thursday. UK legislation would allow that the young adult be detained for treatment, whereas in Ireland they must consent, he said. The court heard the young person had been in special care – the most secure form of care where children at serious risk may be detained by the High Court for their own or the community's safety – for a number of years until the day before their 18th birthday. They had a diagnosed personality disorder – which is not recognised for involuntary admission to a psychiatric institution. An assessment before leaving special care concluded the teenager had capacity. READ MORE Aftercare went well initially but the young adult 'is making decisions which unfortunately were entirely predicted ... but ... making them as a capacitous adult,' said Paul Gunning, barrister for Tusla. Brian Barrington, for the guardian ad litem, a court-appointed independent advocate for the young person, said the teenager was 'on a bleak trajectory' having stabbed themself and been 'stabbed by others' in recent weeks. Shane Costello, for parents, said their child had been discharged without an assigned adult psychiatrist and still had no 'treating adult psychiatrist'. A GP had stopped prescribing antipsychotic medication due to the young person's illicit drug use. 'In summary it's fair to say bleak doesn't quite describe the situation ... [The parents] are distraught. They don't know what more they can do.' Alan Brady, for the HSE, said the executive did not know how 'adding a psychiatrist' would 'assist' where a GP had stopped prescribing medication. 'The Mental Health Act very explicitly excludes detention in that [psychiatric] system for a person with a personality disorder.' The situation underscored the difference between Irish and UK mental health legislation, said Mr Justice Jordan. He was not saying UK legislation was better. 'There is nothing that can be done without [the teenager's] consent, whereas in the UK that would not be so ... The legislation should be looked at again ... because this is happening on this list time and again. ' A teenager for whom a special care order was made two weeks ago remains unable to access a bed. Sarah McKechnie, for Tusla, said the teenager had left hospital, having been admitted after an overdose last week. It was a 'matter of extreme urgency' that the child gets a bed, the court heard. No bed was likely until August 25th. Their parents have issued proceedings against Tusla for alleged failings in their child's care. 'It is completely unsatisfactory the order is not complied with,' said Mr Justice Jordan. 'This young [child] should be in special care and would be if [Tusla] had complied with the order that they applied for and got in this court.' The parents of a young teenager missing from special care since last weekend are 'tremendously concerned', said barrister Donal Ó Muircheartaigh. 'They feel [the child] doesn't have a phone ... doesn't have money. Given the previous concerns around exploitation, they have significant worries in that regard.' The judge said the parents had a 'legitimate complaint' that they were not told their child was missing for more than 24 hours 'not least because they may be able to assist in locating [the child] if they know when [they] goes missing'.

Ozempic-like fat jabs linked to horror side effect that causes sudden blindness, study reveals
Ozempic-like fat jabs linked to horror side effect that causes sudden blindness, study reveals

The Irish Sun

timea day ago

  • The Irish Sun

Ozempic-like fat jabs linked to horror side effect that causes sudden blindness, study reveals

WEIGHT loss jabs could raise the risk of sudden blindness, a study warns. Injections like Wegovy, Mounjaro and Ozempic are all the rage because of their rapid slimming effects – but they are not without side effects. 1 Weight loss jabs' popularity has soared in the past three years (stock image) Credit: Alamy Users mostly report gut problems that tend to end after they stop taking the medicines. But new research warns weight loss jabs might pose a permanent risk to patients' eyes. A study of type 2 diabetes patients taking semaglutide – the ingredient in Ozempic and Wegovy – found a link to non-arteritic anterior ischemic optic neuropathy. The condition, known as NAOIN, causes sudden blindness. Sufferers lose blood supply to the nerve behind the eye, breaking the connection between eye and brain and leaving the eye completely blind. It typically happens quickly and painlessly to one eye and cannot be cured. A study by the US National Institutes of Health analysed data from 3.8million type 2 diabetes patients over the age of 65. It found semaglutide raised the risk by 15 per cent compared to other diabetes medications such as insulin or metformin. Most read in Health Writing in the journal JAMA Ophthalmology, researchers said: 'Our findings demonstrate an association between semaglutide use and an increased risk of NAION.' 'Patient safety is top priority' It adds to a previous study that suggested the medicine increased the risk as much as four to eight times above average. Watch Ellen's weight loss journey on fat jabs The authors of that study said: 'As with any drug, therapeutic benefits are inseparable from adverse effects.' Novo Nordisk, which makes Wegovy and 'In June 2025 we concluded that the data did not suggest a reasonable possibility of a causal relationship between semaglutide and NAION and that the benefit-risk profile of semaglutide remains favourable. 'Novo Nordisk will continue to collaborate with the MHRA to discuss any UK impact. 'We recommend that any patients experiencing side effects while taking our medicines report them to their healthcare provider.' Everything you need to know about fat jabs Weight loss jabs are all the rage as studies and patient stories reveal they help people shed flab at almost unbelievable rates, as well as appearing to reduce the risk of serious diseases. Wegovy – a modified version of type 2 diabetes drug Ozempic – and Mounjaro are the leading weight loss injections used in the UK. Wegovy, real name semaglutide, has been used on the NHS for years while Mounjaro (tirzepatide) is a newer and more powerful addition to the market. Mounjaro accounts for most private prescriptions for weight loss and is set to join Wegovy as an NHS staple this year. How do they work? The jabs work by suppressing your appetite, making you eat less so your body burns fat for energy instead and you lose weight. They do this my mimicking a hormone called GLP-1, which signals to the brain when the stomach is full, so the drugs are officially called GLP-1 receptor agonists. They slow down digestion and increase insulin production, lowering blood sugar, which is why they were first developed to treat type 2 diabetes in which patients' sugar levels are too high. Can I get them? NHS prescriptions of weight loss drugs, mainly Wegovy and an older version called Saxenda (chemical name liraglutide), are controlled through specialist weight loss clinics. Typically a patient will have to have a body mass index (BMI) of 30 or higher, classifying them as medically obese, and also have a weight-related health condition such as high blood pressure. GPs generally do not prescribe the drugs for weight loss. Private prescribers offer the jabs, most commonly Mounjaro, to anyone who is obese (BMI of 30+) or overweight (BMI 25-30) with a weight-related health risk. Private pharmacies have been rapped for handing them out too easily and video calls or face-to-face appointments are now mandatory to check a patient is being truthful about their size and health. Are there any risks? Yes – side effects are common but most are relatively mild. Around half of people taking the drug experience gut issues, including sickness, bloating, acid reflux, constipation and diarrhoea. Dr Sarah Jarvis, GP and clinical consultant at said: 'One of the more uncommon side effects is severe acute pancreatitis, which is extremely painful and happens to one in 500 people.' Other uncommon side effects include altered taste, kidney problems, allergic reactions, gallbladder problems and hypoglycemia. Evidence has so far been inconclusive about whether the injections are damaging to patients' mental health. Figures obtained by The Sun show that, up to January 2025, 85 patient deaths in the UK were suspected to be linked to the medicines.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store